[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2018014560A - Metodos para el tratamiento de la miastenia gravis generalizada refractaria. - Google Patents

Metodos para el tratamiento de la miastenia gravis generalizada refractaria.

Info

Publication number
MX2018014560A
MX2018014560A MX2018014560A MX2018014560A MX2018014560A MX 2018014560 A MX2018014560 A MX 2018014560A MX 2018014560 A MX2018014560 A MX 2018014560A MX 2018014560 A MX2018014560 A MX 2018014560A MX 2018014560 A MX2018014560 A MX 2018014560A
Authority
MX
Mexico
Prior art keywords
myasthenia gravis
methods
treatment
generalized myasthenia
refractory generalized
Prior art date
Application number
MX2018014560A
Other languages
English (en)
Inventor
Bedrosian Camille
O'brien Fanny
Jing Wang Jing
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of MX2018014560A publication Critical patent/MX2018014560A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La divulgación provee métodos de tratamiento de la miastenia gravis (MG) en un sujeto que lo requiere, mediante la administración al sujeto de una sustancia que se une específicamente al componente 5 del complemento (C5). En ciertas modalidades, la sustancia que se une específicamente a C5 es una proteína enlazante, tal como un anticuerpo anti-C5.
MX2018014560A 2016-05-27 2017-05-15 Metodos para el tratamiento de la miastenia gravis generalizada refractaria. MX2018014560A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662342321P 2016-05-27 2016-05-27
US201662346168P 2016-06-06 2016-06-06
US201762489240P 2017-04-24 2017-04-24
US201762500643P 2017-05-03 2017-05-03
PCT/US2017/032767 WO2017205101A1 (en) 2016-05-27 2017-05-15 Methods for treatment of refractory generalized myasthenia gravis

Publications (1)

Publication Number Publication Date
MX2018014560A true MX2018014560A (es) 2019-08-12

Family

ID=60412593

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014560A MX2018014560A (es) 2016-05-27 2017-05-15 Metodos para el tratamiento de la miastenia gravis generalizada refractaria.

Country Status (11)

Country Link
US (2) US20170342139A1 (es)
EP (2) EP3909609A1 (es)
JP (2) JP2019517473A (es)
KR (1) KR20190012199A (es)
CN (1) CN109475630A (es)
AU (1) AU2017269839A1 (es)
BR (1) BR112018073945A2 (es)
CA (1) CA3024618A1 (es)
MX (1) MX2018014560A (es)
RU (1) RU2018141451A (es)
WO (1) WO2017205101A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170342139A1 (en) * 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for Treatment of Refractory Generalized Myasthenia Gravis
FI3468990T3 (fi) 2016-06-14 2024-06-26 Regeneron Pharma Anti-C5-vasta-aineita ja niiden käyttöjä
CN111630065A (zh) 2017-12-13 2020-09-04 瑞泽恩制药公司 抗c5抗体组合及其用途
EP3852874A1 (en) * 2018-09-17 2021-07-28 Kyoto University Administration of an anti-c5 agent for treatment of hepatic injury or failure
US20220002393A1 (en) * 2018-11-20 2022-01-06 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis in pediatric patients
WO2020168079A1 (en) * 2019-02-14 2020-08-20 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis
US20220259305A1 (en) * 2019-08-05 2022-08-18 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis with eculizumab

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
JP4021194B2 (ja) 2001-12-28 2007-12-12 シャープ株式会社 薄膜トランジスタ装置の製造方法
US9415102B2 (en) * 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US7807378B2 (en) * 2005-12-29 2010-10-05 Industrial Technology Research Institute (Itri) Method of diagnosing myasthenia gravis and kits therefor
WO2010015608A1 (en) 2008-08-05 2010-02-11 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
CN102271703B (zh) * 2008-11-10 2015-09-16 阿雷克森制药公司 用于治疗补体相关障碍的方法和组合物
TWI803876B (zh) 2011-03-28 2023-06-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
NZ711451A (en) * 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
US20170342139A1 (en) * 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for Treatment of Refractory Generalized Myasthenia Gravis
US20190328854A1 (en) * 2016-08-29 2019-10-31 The Cleveland Clinic Foundation C5 immunization for autologous anti-c5 antibody production

Also Published As

Publication number Publication date
CA3024618A1 (en) 2017-11-30
KR20190012199A (ko) 2019-02-08
US20170342139A1 (en) 2017-11-30
US20210246196A1 (en) 2021-08-12
RU2018141451A (ru) 2020-06-29
CN109475630A (zh) 2019-03-15
EP3463461A4 (en) 2020-05-20
RU2018141451A3 (es) 2020-09-21
AU2017269839A1 (en) 2018-11-22
EP3909609A1 (en) 2021-11-17
WO2017205101A1 (en) 2017-11-30
BR112018073945A2 (pt) 2019-02-26
EP3463461A1 (en) 2019-04-10
JP2022126773A (ja) 2022-08-30
JP2019517473A (ja) 2019-06-24

Similar Documents

Publication Publication Date Title
MX2018014560A (es) Metodos para el tratamiento de la miastenia gravis generalizada refractaria.
MX2021008053A (es) Metodos para monitorear y terapias para usarse en tratar el cancer.
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
NZ738008A (en) Tigit-binding agents and uses thereof
EA201892294A1 (ru) Антитела и композиции против tim-3
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
MX2022002504A (es) Anticuerpos para cd40.
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
MX2020010530A (es) Anticuerpos humanizados contra cd269 (bcma).
GEP20227369B (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
JOP20180117B1 (ar) أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها
EP3552665A3 (en) Antibodies
CR20210010A (es) Anticuerpos dirigidos contra il-11ra
WO2019014328A3 (en) AGONISTIC ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
MX368228B (es) Anticuerpos que se unen específicamente a her2.
MX2018010672A (es) Anticuerpos para cumulo de diferenciación 40 (cd40) con actividad agonista mejorada.
TN2017000072A1 (en) Combination alzheimer therapy using anti-n3pglu abeta antibodies + a bace inhibitor
MX2020002406A (es) Anticuerpo anti-epha4.
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
EA201691634A1 (ru) Способы лечения отторжения трансплантата с использованием доменного антитела, направленного против cd40l
EA202191666A1 (ru) Антитела к il-27 и их применение
MX2021004351A (es) Metodo para el tratamiento de miastenia grave.
EA201992318A1 (ru) Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
EA201992315A1 (ru) Композиции и способы для лечения рака легкого